carlos-zaragoza

Biography

Name:

Carlos Zaragoza

Title:

Dr.

Institution:

Univ Francisco de Vitoria UFV/Inst. Ramon y Cajal de Inv. Sanitaria IRYCIS

Email:

[email protected]

Website:

www.ufv.es

Early career investigator (ECI):

No

Short biography of member:

PhD in Biology (Genetics) in 1996. Researcher enrolled in the resident programme at The Johns Hopkins University, Department of Cardiology 1996/2000. Specialty: Viral myocarditis. Researcher National Programme Ramón y Cajal, first call 2002/2006 (ranking: 8), accredited with I3 at the National Centre for Cardiovascular Research (CNIC). Head of Laboratory National Center of Cardiovascular Research CNIC (2006-2012). Associate Professor, Department of Physiology, University of Alcalá 2010-2012. Associate Professor, Faculty of Medicine, Universidad Francisco de Vitoria 2012-2014. Full time Professor, School of Medicine University Francisco de Vitoria since 2014. Subjects: Cardiovascular disease and Physiology. Chair of Cardiovascular Research Unit UFV/Cardiology Service of the Hospital Ramón y Cajal 2014-present. Principal investigator of 9 national and international projects, author of over 60 articles on applied research in cardiovascular disease, 1patent granted in Europe and the USA. Index H: 32. Cited: 3025 times. Panel member of national and international experts in the evaluation of projects in the clinical and translational cardiovascular research. Associate editor of specific journals of the cardiovascular area. Director of 6 doctoral theses, final papers and dissertations of master's degree. My laboratory is focused in finding molecular targets with diagnostic and/or therapeutic utility for the treatment of acute coronary syndrome, cardiac remodeling, heart failure, atherosclerosis or aortic aneurysms. We study factors that trigger the inflammatory response and the degradation of extracellular matrix components in the inflammatory context, analyzing the role than vasoactive factors, especially nitric oxide and the enzymes involved, play through the regulation of the expression and activity of enzymes that degrade wall components. Since 2012, and thanks to the partnerships with laboratories experts in the area of non-invasive molecular imaging, one of the most important lines is the evaluation of non-invasive molecular imaging by nuclear magnetic resonance, to carry out not only the visualization of single molecules, but also for the use of nanotechnology for theranostic purposes. We are currently carrying out the applicability of our findings in international cooperation projects.

Country:

ES, Spain

Publications list:

Sci Rep. 2020 Mar 6;10(1):4190

Sci Rep. 2019 Dec 30;9(1):20290

Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):171-174

Biosci Rep. 2019 Mar 15;39(3). pii: BSR20180934

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3248.

Front Physiol. 2018 Jun 14;9:702

Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1272-1281

Rev Esp Cardiol (Engl Ed). 2017 Mar 28. pii: S1885-5857(17)30155-X

J Am Coll Cardiol. 2017 Jan 31;69(4):423-433

PLoS One. 2016 Sep 20;11(9):e0162912

Theranostics. 2016 Feb 15;6(4):545-57

Methods Mol Biol. 2015;1339:367-76

Circ Cardiovasc Imaging. 2015 Apr;8(4)

Cardiovasc Res. 2015 Jun 1;106(3):375-86

FASEB J. 2014 Nov;28(11):4719-28

J Am Heart Assoc. 2014 Aug 4;3(4). pii: e000723

Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1739-46.

PLoS One. 2012;7(9):e45260

Circ Res. 2012 Feb 3;110(3):439-49.